Subsequent Events	9 Months Ended
Sep. 30, 2024
Subsequent Events
Subsequent Events	13. Subsequent Events On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the “Indenture Agreement”) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the “Redemption Date”). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of the Company’s common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024. In November 2024, the Company entered into an agreement with a non-profit research institute and a clinical technology company whereby the Company obtained licensing rights and access to certain data. The Company is obligated to pay a total of $20.0 million, of which $7.0 million has been paid and the remaining $13.0 million will be paid between January 2025 and January 2031. Additionally, the Company may be obligated to pay up to $50.0 million in milestone payments if certain milestone thresholds and regulatory approvals are achieved.

Subsequent Events

9 Months Ended

Sep. 30, 2024

13. Subsequent Events

On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the “Indenture Agreement”) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the “Redemption Date”). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of the Company’s common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024.

In November 2024, the Company entered into an agreement with a non-profit research institute and a clinical technology company whereby the Company obtained licensing rights and access to certain data. The Company is obligated to pay a total of $20.0 million, of which $7.0 million has been paid and the remaining $13.0 million will be paid between January 2025 and January 2031. Additionally, the Company may be obligated to pay up to $50.0 million in milestone payments if certain milestone thresholds and regulatory approvals are achieved.